News & Views
Telix today announces that the first patient has been dosed with TLX101-Tx (¹³¹I-iodofalan) in Telix’s pivotal IPAX BrIGHT trial, marking the first radiopharmaceutical therapy to enter Phase 3 development for glioblastoma,…
Read more
Telix and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN, “Regeneron”) today announce a collaboration to jointly develop and commercialize next generation radiopharmaceutical…
Read more
Telix today announces that the United States (U.S.) Food and Drug Administration (FDA) has accepted the Company’s resubmitted New Drug Application (NDA) for TLX101-Px, (Pixclara®, Floretyrosine F 18 or 18F-FET), an…
Read more
Telix today announces two additional Non-Executive Director (NED) appointments, effective May 11, 2026, as part of Board expansion and succession…
Read more
Telix provides a market update on its commercial and operational performance for the quarter ended March 31, 2026 (Q1…
Read more
Telix today announces the appointment of David Gill as a Non-Executive Director (NED), as part of Board expansion and succession planning. The appointment is effective May 11, 2026. Mr. Gill…
Read more
News,
Liz Leff was diagnosed with clear cell renal cell carcinoma (ccRCC) in 2014. The experience shaped everything that followed, including a career in patient advocacy that eventually brought her to…
Read more
News,
Maggie Valdes Butera’s husband Brandon was diagnosed with kidney cancer in 2021 at the age of 26. He passed away in 2024. We spoke to Maggie about their journey together,…
Read more
Telix today announces the resubmission of a New Drug Application (NDA) to the United States (U.S.) Food and Drug Administration (FDA) for TLX101-Px, (Pixclara®, Floretyrosine F 18 or 18F-FET), an investigational…
Read more
Telix today announces that Part 1 of the ProstACT Global Phase 3 study, the safety and dosimetry lead-in for its therapeutic candidate – TLX591-Tx (lutetium-177 (177Lu) rosopatamab tetraxetan) – has…
Read more